Syros Pharmaceuticals Gets a Buy Rating from Oppenheimer

By Carrie Williams

Oppenheimer analyst Leah R. Cann reiterated a Buy rating on Syros Pharmaceuticals (NASDAQ: SYRS) today and set a price target of $28. The company’s shares opened today at $17.63.

R. Cann commented:

“Syros announced today that data from its ongoing efforts to understand gene regulatory networks in autoimmune diseases were presented at a scientific conference. This work identified genomic alterations in immune cells derived from patients with systemic lupus erythematosus (SLE). This is early-stage, basic-science research and does not impact our outlook through 2021.”

According to TipRanks.com, Cann is a 4-star analyst with an average return of 6.6% and a 64.7% success rate. Cann covers the Healthcare sector, focusing on stocks such as CytomX Therapeutics Inc, Seattle Genetics, and Acceleron Pharma.

Syros Pharmaceuticals has an analyst consensus of Moderate Buy, with a price target consensus of $19.

The company has a one year high of $21.50 and a one year low of $8.16. Currently, Syros Pharmaceuticals has an average volume of 35.74K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Syros Pharmaceuticals, Inc. engages in the development of novel gene control therapies for cancer and other diseases. It has developed a proprietary platform that is designed to systematically and efficiently analyze unexploited region of DNA in human disease tissue to identify and drug novel targets linked to genomically defined patient populations. The company focuses on developing treatments for cancer and immune mediated diseases and is building a pipeline of gene control medicines. Syros Pharmaceuticals was founded by Richard A. Young, Nathanael S. Gray and James E. Bradner on November 9, 2011 and is headquartered in Cambridge, MA.